Diagnostics

No Image

Jack Young, Qualcomm Life Sciences Director, Discusses Mobile Health and Patient Management

December 6, 2012 OneMedPlace Team 0

Young’s experience in both sectors makes him a unique voice in the osmosis of venture capital between mobile technology and life sciences. Young will participate in a panel dedicated to the subject at the 6th Annual OneMedForum in San Francisco, January 7-9. OneMedRadio spoke with Jack Young about investing in this sector, and the points of significant unmet medical need which represent the most promising opportunities.

No Image

`OneMedForum` Panel to Address the Major Opportunities in Digital Health at San Francisco Conference

December 5, 2012 OneMedPlace Team 0

OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Connected Health,’ an emerging sector with significant and diverse investment opportunities.

No Image

Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease

November 28, 2012 OneMedPlace Team 0

Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

No Image

Diagnostics: Biomarkers, Gene Patents, and Personalized Medicine in Jeopardy

November 19, 2012 OneMedPlace Team 1

Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.